



May 2018

PDF

Is it O.K. to Publish Your Life Sciences Invention Before Filing for a Patent?



by **Gerson S. Panitch, Paula E. Miller**

Particularly in the life sciences arena, there is a tendency to reveal innovations and publish findings as soon as possible. These instincts stem from a scientist's academic roots where there is a notable emphasis on "being the first to publish." But what is best in academia is usually not best in business. In a rush to publish, inventors often forget that in most of the world, the publication of an invention before a patent application is filed completely prevents the inventor from getting a patent. So the academic mindset of publishing first can destroy the value of a company. Without patent protection, anyone is free to copy an invention. If money sits in front of you on the table and someone runs up and takes it, that's called theft. It's illegal. But if you publicly reveal your invention without filing for a patent first, someone who copies it is not considered a thief, but is rather considered a smart business person. To learn about best practices, [click here](#).



Recent Developments in Intellectual Property Related to Medicine

by **Susan Y. Tull**


The past year has seen a surge in innovation in the medical and life science fields. Newly published patent application and granted patents reveal applications of artificial intelligence software as a medical device, and nanotechnology to these fields. [Click here](#) to read more on recent developments.

Patent Strategy Course for MBA Students this Summer at Tel Aviv University



July 15-19, 2018 | Tel Aviv

After receiving the outstanding lecturer award last year at Tel Aviv University's Collier School of Management, Finnegan partner Gerson Panitch returns to repeat the MBA course again this summer. As business schools recognize that strong , strategic patents are critical to corporate valuation, they are adding patent strategy to their curriculum. For more information, visit the Collier School of Management website [here](#).



Webinar: Software as a Medical Device (SaMD): What It Is and How Can We Protect Our Related IP?

Software as a medical device (SaMD) is a rapidly expanding field, melding pharmaceuticals and digital health, from wearable health trackers to apps capable of diagnosing and treating diseases. Fueling the fire are the recent FDA Rules outlining the regulatory requirements for SaMD. This surge in technical development will be met with a growing interest to protect those advances using intellectual property, including utility patents, design patents, and trade secrets. Click [here](#) to download the webinar.



Happy 30th Anniversary to our Israel Practice leader

Thirty years ago this week, Finnegan's Israel Practice Leader, Gerson Panitch finished his law degree at the University of Wisconsin, where three years earlier he completed his engineering studies. "I packed up my car, drove across the country to join Finnegan in Washington, DC., and never considered any other option. I felt so fortunate back then, as I remain today, to have been invited to practice law with the leading IP firm in the world. Then, we were just 75 lawyers in a single office in DC," Gerson remarked. Today, Finnegan spans the globe with 10 offices across the U.S., Europe, and Asia, and a robust Israel practice representing nearly 140 of Israel's leading start-ups and mature companies. Nine years ago, Gerson led the group that launched Finnegan's Israel practice. "The goal then was to bring to Israel the same level of strategic IP work demanded by our leading clients in the U.S., Europe, and Asia. I'm humbled when I hear our Israeli clients tell us that we've achieved that goal," Gerson concluded.



We'd hate to see you go!

The EU General Data Protection Regulation (GDPR) goes into effect on May 25, 2018. After May 25, you will no longer receive our newsletter or other Finnegan content if you have not opted in through our [preferences form](#). To comply with the international data regulations, we ask that you take a moment to select the Finnegan content you'd like to receive via email by completing and submitting a [preferences form](#).

About Finnegan

Finnegan is one of the world's largest IP law firms and a go-to source for Israeli companies. We represent more than 100 of Israel's leading and most sophisticated enterprises, helping navigate IP disputes and patent infringement litigation, counseling on how to strategically protect technology to maximize value, managing patent portfolios, and developing revenue streams through creative patenting and licensing. In the words of *Chambers USA*, "Finnegan's work is nothing short of exceptional." www.finnegan.com
www.finnegan.co.il

Finnegan Resources

Finnegan publishes newsletters, blogs, and *IP Updates* that provide news, statistics, and analysis of recent court decisions. Our blogs focus on [Federal Circuit practice](#), [PTAB practice](#), [trademark and copyright law](#), [patent prosecution and counseling](#), [notable IP developments for FDA-regulated products](#), and [intellectual property practice in Europe](#). To sign-up to receive newsletters, blog posts, or *IP Updates*, please click [here](#).



Follow us on

מידע נוסף, צור קשר עם האחראי על הלקוחות הישראליים, ע"ד גרשון פניטש
03-7219629, gerson.panitch@finnegan.com

www.finnegan.com